Company intelligence / Profile preview

Bionter

Ownership: Private
Development stage: Commercial

Overview

Bionter has developed and commercialized EVE, a patented fully automated particle counter that enables non-destructive sample analysis for injectable drugs. The device increases efficiency, reduces costs and sample size requirements, and complies with regulatory standards. It supports faster and safer drug development by improving quality control in biopharmaceutical manufacturing.

No clinical results as the company does not develop therapeutics.

The company has established partnerships with global pharma companies for prototype testing and commercialization.

Modalities: Device (analytical testing device for parenteral drug applications)
Industry: Drug Discovery Services

Partnerships

Midwest Biosolutions (US-based manufacturer's representative group to drive market growth in North America)

Beyond the preview

Go deeper on Bionter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionter.

Explore the full profile